|
Recent Developments |
|
02-FEB-17
Dishman Pharmaceuticals & Chemicals, a manufacturer of active ingredients, announced that the company's Bavla facility was successfully inspected by the US FDA in July, 2016, which was intimated to the stock exchanges on July 09, 2016.
14-JUL-16
Dishman Pharmaceuticals & Chemicals, a manufacturer of active ingredients, wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, had successfully completed US FDA inspection for i... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015 (12) | 31-Mar-2014 (12) | | Net sales | 4928.07 | 4786.93 | 4719.93 | | Other Income | 621.82 | 669.98 | 559.76 | | Total Income | 5549.89 | 5456.91 | 5279.69 | | Cost of goods sold | 3469.28 | 4178.64 | 2970.70 | | OPBDIT | 2080.61 | 1278.27 | 2308.99 | | PAT | 871.53 | 584.78 | 867.87 | | Gross Block | - | - | - | | Equity capital | 161.40 | 161.39 | 161.39 | | EPS (Rs.) | - | 7.25 | 10.75 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 11.26 - 27.17 | 3.45 - 10.27 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 37.5 | 23.4 | 43.7 | | Net margin (% of OI) | 15.7 | 10.7 | 16.4 |
|
|
Detailed Financials
|
|
|
|
|
